Academic Journal
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines
العنوان: | Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines |
---|---|
المؤلفون: | Al Khaja, Khalid A. J., Sequeira, Reginald P. |
المصدر: | Malaria Journal ; volume 20, issue 1 ; ISSN 1475-2875 |
بيانات النشر: | Springer Science and Business Media LLC |
سنة النشر: | 2021 |
الوصف: | Background Malaria caused by Plasmodium falciparum in pregnancy can result in adverse maternal and fetal sequelae. This review evaluated the adherence of the national guidelines drawn from World Health Organization (WHO) regions, Africa, Eastern Mediterranean, Southeast Asia, and Western Pacific, to the WHO recommendations on drug treatment and prevention of chloroquine-resistant falciparum malaria in pregnant women. Methods Thirty-five updated national guidelines and the President’s Malaria Initiative (PMI), available in English language, were reviewed. The primary outcome measures were the first-line anti-malarial treatment protocols adopted by national guidelines for uncomplicated and complicated falciparum malaria infections in early (first) and late (second and third) trimesters of pregnancy. The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed. Results This review evaluated the treatment and prevention of falciparum malaria in pregnancy in 35 national guidelines/PMI-Malaria Operational Plans (MOP) reports out of 95 malaria-endemic countries. Of the 35 national guidelines, 10 (28.6%) recommend oral quinine plus clindamycin as first-line treatment for uncomplicated malaria in the first trimester. As the first-line option, artemether–lumefantrine, an artemisinin-based combination therapy, is adopted by 26 (74.3%) of the guidelines for treating uncomplicated or complicated malaria in the second and third trimesters. Intravenous artesunate is approved by 18 (51.4%) and 31 (88.6%) guidelines for treating complicated malaria during early and late pregnancy, respectively. Of the 23 national guidelines that recommend IPTp-SP strategy, 8 (34.8%) are not explicit about directly observed therapy requirements, and three-quarters, 17 (73.9%), do not specify contra-indication of SP in human immunodeficiency virus (HIV)-infected pregnant women receiving cotrimoxazole prophylaxis. Most of the guidelines (18/23; 78.3%) state the ... |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
DOI: | 10.1186/s12936-020-03565-2 |
DOI: | 10.1186/s12936-020-03565-2.pdf |
DOI: | 10.1186/s12936-020-03565-2/fulltext.html |
الاتاحة: | http://dx.doi.org/10.1186/s12936-020-03565-2 http://link.springer.com/content/pdf/10.1186/s12936-020-03565-2.pdf http://link.springer.com/article/10.1186/s12936-020-03565-2/fulltext.html |
Rights: | http://creativecommons.org/licenses/by/4.0/ ; http://creativecommons.org/licenses/by/4.0/ |
رقم الانضمام: | edsbas.1CBA6679 |
قاعدة البيانات: | BASE |
DOI: | 10.1186/s12936-020-03565-2 |
---|